SCHEMBL1629223

SCHEMBL1629223

Cc1ccc(C(=C2CCCCC2)c2cc(F)ccc2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
ESR1 P03372 1/20 0.37
PGR P06401 1/20 0.37
CHRM2 P08172 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AR P10275 1/20 0.37
CHRM1 P11229 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
ALDH1A1 P00352 5/20 0.35
ACHE P22303 1/20 0.34
MDM2 Q00987 2/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
RXRA P19793 1/20 0.33
NFE2L2 Q16236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630754 0.82 OPRM1 (0.48) CES2CES1ESR1PGRCHRM2
SCHEMBL1629224 0.80 OPRM1 (0.49) CES2CES1ESR1PGRCHRM2
SCHEMBL10071627 0.79 ESR1 (0.47) ESR1PGRCHRM2ADORA3AR
SCHEMBL10042117 0.77 OPRM1 (0.49) CES2CES1ALDH1A1ACHEOPRM1
SCHEMBL1630713 0.77 CES2 (0.39) CES2CES1ESR1PGRCHRM2
SCHEMBL401798 0.75 NR4A2 (0.46) ALDH1A1LMNA
SCHEMBL1630082 0.71 CES2 (0.55) CES2CES1ALDH1A1MDM2LMNA
SCHEMBL19700438 0.71 ESR1 (0.50) ESR1PGRCHRM2ADORA3AR
SCHEMBL21384863 0.67 OPRD1 (0.61) ACHEOPRM1OPRD1NFE2L2
SCHEMBL14289911 0.65 ACHE (0.52) CES2CES1ESR1PGRCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470872-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2013-06-25 US disclosed
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA CES2 123/4885CES1 261/4885ESR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.